Group 1 - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao for cash, which is expected to constitute a major asset restructuring [1] - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Cloning, with a transaction value of up to 1.256 billion yuan [1] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 400-600 million USD for four VLCCs, expected delivery between late 2026 and mid-2027 [3] - Qibin Group obtained financing support of up to 90 million yuan for share repurchase [4] Group 3 - Shapuaisi's shareholder plans to reduce holdings by up to 3% of the company's total shares [5] - *ST Kaixin intends to use up to 310 million yuan for cash management in safe and liquid financial products [6] Group 4 - Junchen Technology's shareholders plan to transfer 2.5% of the company's shares due to personal funding needs [7] - Jingliang Holdings received an administrative regulatory measure from Hainan Securities Regulatory Bureau for improper revenue recognition involving 299 million yuan [7] Group 5 - Tongcheng Holdings received a cash dividend of 24.6643 million yuan from Changsha Bank [9] - Shenyang Chemical appointed Chen Liguo as the new general manager [10] Group 6 - Huaguang Huaneng signed a contract for a 160 million yuan waste heat boiler project [15] - Shuxian Valley's subsidiary completed the re-registration of a health food product [16] Group 7 - Xuanta Pharmaceutical's new specification for a diabetes treatment drug was approved [17] - Panlong Pharmaceutical's application for a pain relief gel patch was accepted by the drug regulatory authority [18] Group 8 - Zhiguang Electric's subsidiary won a procurement contract worth 164 million yuan for a storage system [19] - Chitianhua's production facility resumed operations after maintenance [20] Group 9 - Haitong Development's application for a specific A-share issuance was accepted by the Shanghai Stock Exchange, aiming to raise 210 million yuan [20] - Risheng Technology's shareholders plan to transfer 4.02% of the company's shares [33] Group 10 - Pingmei Shares' controlling shareholder plans a strategic restructuring with Henan Energy Group [35] - Shenghui Integration's controlling shareholder committed not to reduce shareholdings for 12 months [37] Group 11 - Agricultural Bank and Bank of China will no longer establish supervisory boards, with their functions transferred to the audit committees [39][40] - Dongfang Yuhong's subsidiary signed a contract for a seawater pipeline project worth 2.524 billion USD [40][41] Group 12 - Ganfeng Lithium plans to introduce investors for a capital increase of up to 2.5 billion yuan [50] - Hanyu Pharmaceutical intends to raise up to 968 million yuan for various projects [51]

| 证券代码：603896 | 证券简称：寿仙谷 | | | 公告编号：2025-063 | | --- | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 | 22 | 转债 | | 浙江寿仙谷医药股份有限公司董事会 2025 年 9 月 27 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江寿仙谷医药股份有限公司（以下简称"公司"）全资子公司金华 寿仙谷药业有限公司"寿仙谷牌灵芝孢子油软胶囊"产品完成了国产保健食品再 注册工作，并获得国家市场监督管理总局发放的国产保健食品注册证书。具体情 况如下： | 产品名称 | 寿仙谷牌灵芝孢子油软胶囊 | | --- | --- | | 保健功能 | 本品经动物实验评价，具有有助于增强免疫力的保健功能 | | 注册号 | 国食健注 G20200107 | | 有效期至 | 年 月 日 2030 08 25 | | 注册人 | 金华寿仙谷药业有限公司 | | 注册人地址 | 浙江省金华市武义县壶山街道商城路 号 10 | | ...

Core Viewpoint - The company has successfully completed the re-registration of its health food product, "Shouxiangu Brand Ganoderma Spore Oil Soft Capsules," and received the registration certificate from the National Market Supervision Administration, indicating its compliance with regulatory standards [1] Group 1 - The product has undergone animal testing and has been evaluated to have health benefits that may help enhance immunity [1] - The registration number for the product is Guo Shi Jian Zhu G20200107, and it is valid until August 25, 2030 [1]

Core Viewpoint - The company is launching a shareholder reward activity to express gratitude to shareholders during the Mid-Autumn Festival, aiming to enhance shareholder engagement and understanding of the company's value [1][5]. Group 1: Activity Details - The activity will take place from September 23, 2025, to October 22, 2025, and shareholders who do not participate within this period will forfeit their rights [1]. - Eligible shareholders include those registered with the China Securities Depository and Clearing Corporation as of September 12, 2025, with individual participation limited to natural persons and corporate shareholders allowed to designate up to five representatives [2]. - During the activity, shareholders can purchase specific products at exclusive discounted prices, with a limit of one purchase per person [3]. Group 2: Participation Process - Natural person shareholders can participate by scanning a QR code for the shareholder reward activity, while corporate representatives must complete identity verification through a separate QR code [4]. - The company provides contact information for inquiries regarding the activity, ensuring shareholders can seek assistance if needed [5]. Group 3: Additional Information - The activity is not classified as a profit distribution and participation is voluntary; shareholders who fail to complete necessary procedures will not have claims against the company [6]. - The company retains the final interpretation rights of the activity, emphasizing fairness and transparency [5].

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-062 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 中秋佳节将至，为建立长效、多样的股东回报机制，更借传统节日之韵传递 感恩心意——感谢广大股东长期以来对浙江寿仙谷医药股份有限公司（以下简称 "公司"或"寿仙谷"）的关心与支持，同时让股东在共话中秋、同品佳节意蕴 的氛围中，更好地了解和体验公司产品，深化对公司内在价值的理解与认识，公 司特开展"寿仙谷 2025 年股东回馈"活动。现将活动内容公告如下： 一、活动时间 2025 年 9 月 23 日 00 时至 2025 年 10 月 22 日 12 时。未在该时段参与活动 的，则视为股东自动放弃参与本次活动的权利。 二、参加活动股东范围 截至 2025 年 9 月 12 日（寿仙谷 2025 年第一次临时股东大会股权登记日） 收市后在中国证券登记结算有限责任公司上海分公司登记在册的公司股东，可 以参与本次活动。自然人股东仅限本人参与，法人股东限指定不超过 5 名（含 5 名）自然人代表。 三、活动内容 ...

Core Viewpoint - The company, Zhejiang Shouxiangu Pharmaceutical Co., Ltd., is launching a shareholder reward program in celebration of the Mid-Autumn Festival, aiming to express gratitude to shareholders and enhance their understanding of the company's products and intrinsic value [1]. Group 1: Shareholder Reward Program - The company is conducting the "Shouxiangu 2025 Shareholder Return" activity to establish a long-term and diverse shareholder return mechanism [1]. - During the event, shareholders and their representatives can purchase specific products at exclusive discounted prices, with a limit of one purchase per person [1]. Group 2: Product Offerings - The following products are available for shareholders at discounted prices: - Shouxiangu Xianzhi No. 3 Broken Wall Ganoderma Spore Powder Tablets (去壁款) - Original price: 4752 RMB, Shareholder price: 3299 RMB [2]. - Shouxiangu Xianzhi No. 3 Broken Wall Ganoderma Spore Powder (去壁款) - Original price: 2720 RMB, Shareholder price: 1900 RMB [2]. - Shouxiangu Sugar-Free Iron Skin Maple Bean Granules (2g*10 bags/box) - Original price: 1192 RMB, Shareholder price: 828 RMB [3].

Group 1 - The core idea of the article is that Shouxiangu (603896.SH) is launching a shareholder reward activity in celebration of the Mid-Autumn Festival, aiming to establish a long-term and diverse shareholder return mechanism while expressing gratitude to shareholders for their support [1] - During the event, shareholders and their representatives can purchase specific products at exclusive discounted prices, with a limit of one purchase per person [1] Group 2 - The products available for purchase include: - Shouxiangu Xianzhi No. 3 Broken Wall Ganoderma Spore Powder (去壁款) at a regular price of 4752 yuan, discounted to 3299 yuan for shareholders [2] - Shouxiangu Xianzhi No. 3 Broken Wall Ganoderma Spore Powder (去壁款) at a regular price of 2720 yuan, discounted to 1900 yuan for shareholders [2] - Shouxiangu Sugar-Free Iron Skin Maple Bean Granules (2g*10 bags/box) at a regular price of 1192 yuan, discounted to 828 yuan for shareholders [3]

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-062 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 | 22 转债 | | 浙江寿仙谷医药股份有限公司 关于 2025 年股东回馈活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中秋佳节将至，为建立长效、多样的股东回报机制，更借传统节日之韵传递 感恩心意——感谢广大股东长期以来对浙江寿仙谷医药股份有限公司（以下简称 "公司"或"寿仙谷"）的关心与支持，同时让股东在共话中秋、同品佳节意蕴 的氛围中，更好地了解和体验公司产品，深化对公司内在价值的理解与认识，公 司特开展"寿仙谷 2025 年股东回馈"活动。现将活动内容公告如下： 一、活动时间 2025 年 9 月 23 日 00 时至 2025 年 10 月 22 日 12 时。未在该时段参与活动 的，则视为股东自动放弃参与本次活动的权利。 二、参加活动股东范围 截至 2025 年 9 月 12 日（寿仙谷 2025 年第一次临时股东 ...

Core Viewpoint - The company announces a shareholder reward event scheduled from September 23 to October 22, 2025, allowing eligible shareholders to purchase products at discounted prices [1] Group 1: Event Details - The shareholder reward event will take place from September 23 to October 22, 2025 [1] - Eligible shareholders can purchase products such as Shouxiangu Xianzhi No. 3 broken-wall Ganoderma lucidum spore powder tablets and sugar-free iron skin maple granules at preferential prices [1] - Individual shareholders must participate by scanning a QR code via WeChat, while corporate shareholders need to submit identification and undergo verification [1] Group 2: Company Policy - The event does not constitute a profit distribution, and the company retains the final interpretation rights regarding the event [1]

Group 1 - The 22nd China International Health Expo opened in Xiamen, focusing on "National Health" and showcasing the achievements of the health industry over the past 30 years [1] - Shouxiangu was awarded the title of "Leading Enterprise in Tribute to 30 Years of Health Industry Development" during the expo [1] - The expo emphasized green development, low-carbon environmental protection, and digital transformation, aiming to build a global health industry communication platform [1] Group 2 - Shouxiangu set up a 100 square meter exhibition hall, integrating brand display, cultural experience, and technological interaction, showcasing its research and industrialization achievements in the field of Ganoderma [2] - The company has established the world's largest Ganoderma genetic resource bank, preserving over 13,000 genetic resources and has developed multiple Ganoderma varieties [2] - Shouxiangu's cultivation base has received organic certification from various regions including China, the EU, the US, Japan, and Canada [2] Group 3 - The company developed the "third-generation wall-breaking technology for Ganoderma spore powder," which reportedly enhances the content of active ingredients and human absorption rates, winning a gold medal at the Geneva International Invention Exhibition [2] - In its digital transformation, Shouxiangu has built a collaborative system across the entire industry chain, including "smart farms, smart factories, smart markets, and smart laboratories" [2] - The cultivation end has implemented an "intelligent adaptive organic cultivation model," increasing the yield of medicinal materials by 50%-80% and improving the stability of active ingredients by 35% [2] Group 4 - At the expo, Shouxiangu displayed three core product series: Ganoderma, Dendrobium, and Saffron, covering traditional Chinese medicine products and health foods [2] - The company also showcased national intangible cultural heritage techniques, including "Wuyi Shouxiangu Traditional Chinese Medicine Processing Skills" and "Tiepi Fengdou" production techniques [2] - Shouxiangu's chairman emphasized the importance of traditional Chinese medicine and the company's commitment to technological innovation and cultural heritage to enhance the Ganoderma industry [2]